AS1411, a nucleolin targeting aptamer that had been tested as an anticancer agent in Phase II clinical trials, could stimulate macropinocytosis to promote drug uptake in cancer cells but not nonmalignant cells (Reyes-Reyes et al., 2010), suggesting the potential application of macropinocytosis process in drug delivery for cancer treatment. The gene discussed is NUCLEOLIN; the disease is cancer.